Nicox notes Bausch + Lomb's submission of Vesneo with US FDA

France-based biopharmaceutical company Nicox (Eueronext Paris: COX) on Friday noted Bausch + Lomb confirming the submission of a New Drug Application (NDA) with the US Food and Drug Administration for Vesneo.

Vesneo (latanoprostene bunod ophthalmic solution), is a single-agent eye drop for patients with open angle glaucoma or ocular hypertension.

The data submitted in the NDA supports Vesneo as the first nitric-oxide donating agent for ophthalmic use. Last year,  Nicox partnered with Bausch + Lomb to co-promote latanoprostene bunod.